Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00586521 · ClinicalTrials.gov registry record · Phase 4
BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)
A Phase 4 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00586521 is a Phase 4 study that has completed, run by Bayer. The registered enrollment target is 20 participants.
The verdict
NCT00586521, a Phase 4 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effect of prophylactic treatment on the number of joint bleeds and quality of life in severe hemophilia A subjects compared to on-demand treatment in a one-group two-treatment schedule design. In addition, the effect of prophylactic treatment on the joint function, the number of all bleeds, and on the quality of life compared to on-demand treatment and health-economic data will be assessed.
Interventions
- DRUG Kogenate (BAY14-2222)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-02 |
| Est. Completion | 2008-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00586521
The ClinicalTrials.gov registry entry for NCT00586521 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Kogenate (BAY14-2222) is the first listed.
NCT00586521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00586521 about?
NCT00586521 is a clinical study titled "BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)". The purpose of the study is to evaluate the effect of prophylactic treatment on the number of joint bleeds and quality of life in severe hemophilia A subjects compared to on-demand treatment in a one-group two-treatment schedule design. In addition, the effect of prophylactic treatment on the joint...
What is the current status of trial NCT00586521?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2006-02. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00586521?
The interventions under investigation include: Kogenate (BAY14-2222) (DRUG).
Who is sponsoring clinical trial NCT00586521?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.